Clareo Health | Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Neumora Therapeutics, Inc.
Age
55–90
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Part A
Healthy participants
Age 65 to 80 years
Body mass index (BMI) ≥18.0 and ≤32.0 kg/m\^2 at the screening and check-in visit
Part B
Participants aged 55 to 90 years
Diagnosis of probable AD or Alzheimer's clinical syndrome according to the National Institute of Aging-Alzheimer's Association criteria at least 12 months prior to screening
Agitation meets the International Psychogeriatric Association (IPA) consensus definition
Mini-Mental State Examination (MMSE) score = 5 - 24 (mild to severe dementia) at screening
You may not be if
Part A
Participant is actively suicidal
Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit
Diagnosis of epilepsy taking anticonvulsants for seizure control, history of seizures
Part B
Dementia or memory impairment due to a reason other than AD
Clinically significant neurologic disorder other than AD
Have any clinically significant and uncontrolled medical condition
